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ABSTRACT
Clise, Megan Kathleen. MS. The University of Memphis. December 2012. The
connection of the parental understanding of phenylketonuria and demographic
information to recommended treatment blood levels of phenylalanine of children in their
care. Major Professor: Margaret R. Williams.
Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism. In PKU
phenylalanine cannot be converted to tyrosine; when phenylalanine levels remain
elevated intellectual disabilities, as well as other side effects, can occur. These side
effects can be prevented if the phenylalanine levels remain within treatment range. The
purpose of this study was to determine if parents’ understanding of PKU and
demographics affected the children’s phenylalanine level. A questionnaire was developed
to assess the parents’ understanding and demographics; these were then correlated to the
child’s average blood phenylalanine levels using Pearson’s Correlation. The strongest
relationship to the child’s blood phenylalanine level was a negative relationship with the
parents’ understanding of the disorder. Other variables examined were parental age,
number of children, employment, income, education, and marital status. In conclusion,
the study demonstrated the need for parents to understand their child’s disorder for
improved management of PKU.
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CHAPTER I
REVIEW OF LITERATURE
Introduction
Phenylketonuria, more commonly referred to as PKU, is an autosomal recessive
inherited disorder (1). An autosomal recessive disorder is a disorder where both parents
must be carriers or have the disorder themselves to pass it on to their children (2). The
phenylalanine hydroxylase (PAH) enzyme which allows tyrosine to be synthesized from
phenylalanine (phe) is deficient in this disorder (2). Patients that have this disorder are
unable to or have a lessened ability to convert phenylalanine to tyrosine, resulting in a
buildup of phenylalanine and an insufficiency of tyrosine in the blood (1, 2). Similar to
other inborn errors of metabolism, it is possible for the enzyme to still be partially
working, hence the possibilities of varying severities. Newborn screening is typically
done in the United States (US) on disorders which are considered treatable (3). The
recommendations for the diet of a patient with PKU have changed since the disorder was
recognized. Currently, research agrees that anyone with PKU should follow a phe
restricted diet for life (1), whereas previously many children would not remain on the
PKU diet even throughout their complete childhood (4). The difficulty with a phe
restricted diet is that natural protein must be limited which can cause a lack of tyrosine in
the blood (5). Therefore, tyrosine is supplemented in the diet. If the diet of a child with
PKU is not strictly monitored, the amino acid phe may exceed the treatment range of 2.06.0 mg/dL (120-360μmol/L) in the blood. It is important to maintain the phe levels within
the desired range due to the vast side effects that can occur. If phe levels are not
maintained within the treatment range, some side effects that can occur include: brain
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damage, intellectual disabilities, behavioral problems, as well as neurological issues (6).
It has been shown that restricting phe has lessened the likelihood of these side effects (6).
Newborn Screening
Newborn screening is currently conducted for many genetic disorders in the US
(7). Newborn screening for PKU began in 1968 in the state of Tennessee. Prior to this,
many people would already have developmental delays by the time they were classified
as having PKU (8). According to an article by Campbell, newborn screening was
mandatory in all states, except Maryland and Wisconsin in 2003(3). However, more
recent research shows that by law, PKU is screened for in all fifty states (7). In current
screenings, if the plasma phe levels are between 360- 1200μmol/L (6-20mg/dL) it is
considered mild or moderate PKU. If the levels are greater than 1200μmol/L (20mg/dL),
that typically indicates “classical” PKU (9, 10). A range from 120-480mmol/L (2-8
mg/dL) on a normal diet is termed hyperphenylalaninemia (11). Screening is usually
conducted on infants within 24-48 hours of life by a heel stick blood sample method; if
their levels come back elevated they will be referred to see a geneticist and dietitian. The
infant will be screened again to confirm that the phe levels are elevated, and if so, the
medical team will create a plan for the family to follow.
Prior Recommendations
Previously to Schuett’s research showing the effect of long term low phe diets on
children, the importance of remaining on a low phe diet after being diagnosed with PKU
was unknown (4). It was thought that after the brain was developed in size, at
approximately age 6, it was acceptable to be taken off the diet. In order to evaluate this,
2

Schuett looked at 151 children with PKU and whether or not they remained on a low phe
diet or were taken off. She noted that the wide array of ages when children were
removed from the diet was linked to each clinician’s personal feelings and the family
members decision that it was time for the child to be removed from the diet (4). Schuett
demonstrated that children taken off of the diet had decreases in IQ and that their
behavioral issues worsened after being taken off of the diet (4). At the time of this study,
common medical therapy was to keep the phe level below 1200 mg/dL (10mg/dL) (4).
Current Recommendations
A study by Koch described the difference in the development of the children that
remained on or were taken off the PKU diet (12). Due to the expanded research on the
development of patients that remained on the PKU diet the “philosophy of ‘diet for life’”
came about (12). It is also recommended that a metabolic clinic is visited frequently,
especially during adolescence, when growth is often occurring at a rapid rate (13).
Currently the treatment range is a phe level between 2.0-6.0 mg/dL (120-360 μmol/L)
(1). Although the prior treatment range was determined to be too high, medical
professionals still thought that a phe level of 1200 mg/dl was acceptable in adults and
relaxed the management of the PKU in adults; however there is still not a specific
recommended treatment range, due to the variation of side effects that occur differently in
patients (14). Due to the large number of enzyme defects there are several possible
management options for this disorder (13). Today, the main treatment of a child with
PKU is restricting the phe intake, which is done by restricting intact protein, and
supplementing with synthetic essential amino acids from a formula without phenylalanine
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included, as it would be with natural protein. There are alternative treatment choices for
some patients with PKU.
Current Treatment Options
A current treatment option is to administer a cofactor, tetrahydrobiopterin (BH4),
that assists in the synthesis of tyrosine from phenylalanine (15). Tetrahydrobiopterin
supplementation has been shown to reduce blood phe levels, increase PAH enzyme
activity, and increase dietary protein intake (16). Supplementation of this coenzyme does
allow some patients to have a less restricted diet; however it does not resolve PAH
deficiency (15). BH4 is said to be responsive if there is a 30% decrease in blood phe level
concentrations (9). Recently it has also been found that sapropterin dihydrochloride, a
stable form of BH4 can be ingested orally and decrease the phe levels in the blood.
Vernon did a study at John Hopkins hospital and determined that 62% of the 29 patients
given the sapropterin dihydrochloride were responders and moreover saw a decrease in
their phe levels (17). The synthetic form sapropterin dihydrochloride, branded as
KUVAN ®, has also shown to be effective (17, 18). Studies have shown patients with
more mild types of PKU, such as hyperphenylalaninemia are more likely to respond to
this type of treatment (18).
Glycomacropeptide (GMP), an intact protein that is made in the production of
cheese, is also a possible emerging treatment option (18). Phenylalanine is an aromatic
amino acid, and GMP naturally does not have any aromatic amino acids (19). Ney
explained that GMP supplemented with Indispensible Amino Acids (IAA) could be used
as a treatment option (19) and is currently being used in some medical foods, such as
Cambrooke’s BetterMilk (20).
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Large Neutral Amino Acid (LNAA) Therapy is used for treatment in older adults
along with a phe restricted diet (18). High blood levels of phe can cause an inhibition of
certain amino acids to the brain; this is due to phe’s high affinity for the facilitative
transport system of the blood-brain barrier. Moreover, due to phe’s high affinity other
amino acids, some of which are used in the production of dopamine and serotonin, are
often inhibited from reaching the brain. This in turn, results in a decreased production of
dopamine and serotonin, neurotransmitters that regulate mood (21). LNAAs share
common transporters across the intestinal cell membrane and blood-brain barrier;
therefore, when LNAAs are supplemented, dopamine and serotonin production are not
decreased and behavior has been shown to improve (18, 21). Moreover, LNAAs can be
supplemented in order to reduce phe levels in the brain, as LNAAs compete with phe for
uptake (18, 21). This is important in adults because their behavior, attention problems,
and work performance are often interrelated to their phe levels (22).
Possible Future Treatment Options
Alternative treatment methods have been an ongoing quest since the diagnosis of
the disorder (18). Two areas of possible future treatment methods include enzymatic
supplementation, similar to BH4, and gene therapy. Research has been done in Canada on
enzyme substitution with Phenylalanine Ammonia Lyase (PAL), which converts phe to
trans-cinnamic acid and ammonia (18, 23). In this study Sarkissian used PAL in mice as a
substitute for PAH, because it does not require a cofactor (23). The study showed PAL
substitution to be effective in mice short term and is currently going through trials in
humans (18). Gene therapy has been shown to be effective in PKU mice by introducing
the PAH gene, which in turn resulted in expression of the enzyme and reductions in blood
5

phe (18). However, after a patient with unknown complications that was enrolled in a
clinical trial died, more research needs to be done before use in humans (18).
Parental Effect on Well-Being
Parents are often responsible for their children’s outcomes because they control
the diet of their children. A study by Phengxay demonstrated that the knowledge of
mothers of children in Laos that were less than five years of age (n=798) effected the
children’s nutrition level and if the children’s growth was stunted (24). Choi and
colleagues looked into the effect that maternal knowledge had on the blood levels of
children with anemia and they determined that mothers that had a better overall education
and understanding of an iron-rich diet were less likely to have children that were anemic
(25). Another study posted in the Journal of the American Dietetic Association concluded
that mothers who had lower educational levels were more likely to emotionally feed their
child (26). Moreover, Snoek and colleagues determined how adolescents that felt as if
they had a lower amount of maternal support had a greater likelihood of emotional eating.
(27). Although all of these studies were not done with children who had PKU, they all
demonstrate how parents have an effect on the child’s well-being and are relevant to this
study.
In PKU it is vital to limit the natural protein intake and consume an appropriate
amount of medical food or formula. In children, the parent is responsible for maintaining
these goals (28). “This in turn is likely to be influenced by the parents’ understanding of
the low phenylalanine diet, motivation, organizational skills, family cohesion, social
support, and overall coping ability” (28). All of these aspects of the parent(s) life play a
role in the development of the child (28). If the child’s protein and medical food intake
6

are not managed correctly, brain damage and intellectual disability could occur (6).
MacDonald and colleagues performed a study with 46 children aged between 1 and 10
years old and their mothers to determine how the mothers’ educational level and dietary
knowledge affected the children’s blood levels. The study concluded that maternal
knowledge affected the annual median phenylalanine blood levels in their children (28).
Conclusion
In summary, Phenylketonuria is a genetic disorder which blocks the production of
the amino acid tyrosine from phenylalanine in varying degrees. If untreated or if the
recommended diet is not followed correctly, PKU can cause intellectual disabilities.
Thus, although many treatments and outcomes have been studied in children with PKU, a
lack of parental knowledge could significantly impact the child’s blood phe levels and
cause multiple health risks. Therefore, the purpose of this study was to determine if
parental knowledge of PKU and the diet treatment affect the blood levels of
phenylalanine of children in their care.
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CHAPTER II
METHODOLOGY
Subjects
Study subjects were children diagnosed with PKU under the age of fifteen and
their parents. The children involved in the research were patients at the University of
Tennessee’s Health Science Center- Boling Center for Developmental Disabilities
(BCDD). During the child’s scheduled appointment the parent(s) were asked for their
consent to complete the study determining the relationship of the understanding of PKU
to total phenylalanine levels. Depending on the child’s age they were also asked for their
consent or assent to participate. There were a total of fourteen possible participants; six of
the possible participants came to an appointment during the recruitment period with a
parent. All of these patients parents agreed to participate and signed informed
consent/assent.
Research Design
Participants are seen periodically at the BCDD for follow up of their disorder. The
follow-up appointments consist of a blood draw to determine their blood phe and tyrosine
levels and a nutrition assessment is completed by one of the dietitians on staff. The
parents are asked to bring a three-day food record which is reviewed with the dietitian
and later analyzed using MetabolicPro software. Diet analysis values are compared to
laboratory values to determine if a diet prescription change is needed to keep blood levels
within treatment range.
After meeting with the dietitian the parent(s) were asked to participate in the
study, and sign the consent form. Upon both subjects’ consent to participate and
8

signature of the appropriate forms, the survey was read to the parent, which took less than
ten minutes to complete. The parents had to complete the survey during the time of the
appointment. The survey was developed by compounding information from previous
surveys with modifications based on clinical experiences and by adding demographic
questions. The questionnaire was divided into demographic, understanding of PKU, and
child specific questions (Appendix A). The understanding of PKU questions were used to
decipher the parents’ knowledge about PKU and the dietary treatment. In order to
determine this, the questionnaire was scored based on the number of correct answers.
Upon completion of scoring the surveys the child’s medical record was reviewed and the
average blood phenylalanine level from the last year was determined.
Statistical Methods of Data Analysis
IBM SPSS Version 20, 2011 statistical software was used to enter and analyze the
data. Pearson correlations were calculated to determine if there were relationships
between the average phe blood level and the understanding of PKU or the demographic
background of the families who completed the surveys. Due to the small number of
participants significance was not investigated, but rather the type of relationship between
the variables. Both positive and negative relationships were found. A positive
relationship is one in which the variables trend in the same direction, while a negative
relationship is one in which the variables go in separate directions. Once analyzed, a table
was formulated based on SPSS results.
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CHAPTER III
RESULTS
The results presented in Table 1 demonstrate the relationship between the child’s
average phenylalanine blood level and parental understanding of Phenylketonuria or
different parental demographic variables.The strongest relationship was between the
number of correct answers on the questionnaire and the average blood phe levels; this
was a negative relationship. Parents who had higher questionnaire scores typically had
children with lower phe levels as seen in Table 2. The remaining variables, listed in
relation to questionnaire scores from strongest to weakest, were: parental age, number of
children, employment status, income, education, and marital status.

Table 1. Relationship of parental understanding of Phenylketonuria and parental
demographic information to blood phenylalanine levels.
Pearson Correlation to Average Blood
Type of Relationship
Phe Levels
Number Correct
.899
Age Group
.806
+
Number of Kids
.563
Employment
.439
Income
.375
+
Education
.124
+
Marital Status
.083
-
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Table 2. Children’s Average Phenylalanine Levels and Parental Knowledge of
Phenylketonuria Scores
Children’s Average Phenylalanine
Parental Knowledge of Phenylketonuria Score
Levels
4.5
7/7 (100%)
4.4
7/7 (100%)
6.2
6/7 (86%)
7.0
7/7 (100%)
15.6
5/7 (71%)
4.5
7/7 (100%)
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CHAPTER IV
DISCUSSION
Although earlier research has shown a relationship between maternal knowledge
and phenylalanine levels in children with PKU in their care, the parental knowledge and
demographics have never been assessed as to their relationship with phe levels in these
children. The current study evaluated the parental understanding of PKU, as well as some
demographic factors of the parents in relation to the children’s phe blood levels. This was
done by providing the parents with surveys and then correlating this data to the child’s
average phenylalanine levels from the last year of treatment.
Similar to earlier research, the current study demonstrated that the parental
understanding of PKU does have an effect on the phe blood levels of children in their
care (28). Schuett validated that children who are taken off the PKU diet earlier are more
likely to have lower IQs and more intellectual disabilities, which shows the importance of
how the treatment for PKU has changed throughout history. Currently it is recommended
that patients remain on diet for life with a blood treatment range of 2.0-6.0 mg/dL (4, 1).
Moreover, ensuring the PKU diet is followed and that phe levels stay within the treatment
range is vital, this is demonstrated when levels are elevated for periods of time and
intellectual disabilities, behavioral issues, brain damage and other side effects can occur
(6). Due to the small number of participants in the study the relationship between
variables was tested, and not significance. The strongest relationship (-.899) found
demonstrates that in the participants of this study, the children of parents with higher
understanding of PKU had lower average phe levels. This is as predicted, due to the fact
that many parents are responsible for their children’s care a limited knowledge of the
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PKU, would likely affect their care, in turn reflecting in an increased blood phe level in
their children. The next strongest relationship (.806) shows that as parents age typically
the child’s average phe level increases. This information demonstrates that as parents
grow older their children’s blood phenylalanine levels also grow larger. Many would
likely believe this is due to an independency of the child as they age, however in this
study younger children had higher blood phe levels. Another relationship (-.563)
discovered the larger the number of children in the family, the lower the phe levels
typically were. Weaker relationships were found between employment status (-.437),
income (.375), education level (.124), and marital status (-.083). As the samples all had
some type of relationship, it is important to understand the limitations of this study,
which could affect the end results.
Limitations
One limitation of this study is the small sample size. Due to the small sample size,
significance tests could not be performed and the ability to accurately assess the
relationship between parental understanding of PKU and parental demographics and the
phenylalanine blood levels of the children was limited. Another limitation may be that
participants had to complete the survey during their appointment. Many times parents are
not able to bring their children to the appointments and the children would be
accompanied by another family member. This in turn could be one of the reasons why the
sample size was limited.
Another limitation is that the data was collected from one clinic. Although there
was diversity between the participants the fact that the participants are all followed by the
same medical team could impact their results. A limited source of information, such as
13

one medical team, may lead to altered information to the patients. This may occur in part
due to biases and beliefs certain centers may have leading them to possibly include or
exclude certain information, which could ultimately alter results. The wide age range
used in this study could also be a limitation. As children grow their blood phe levels
fluctuate more rapidly than when they are not in a growth spurt. Using infants in this
study may have altered the results, as they are growing rapidly and it can be difficult to
maintain their blood phe levels within the treatment range. Although there was diversity
between the sample used, a larger sample size would have given a larger demographic
variance.
Conclusion
The relationship between parental knowledge of Phenylketonuria and the phe
levels of children younger than fifteen in their care suggests that understanding PKU and
its treatment does positively affect the child’s blood levels. The parental age and number
of children were also suggestive to impact phe levels. Less strong relationships were
found between phe levels and employment status, income, education, or marital status.
Moreover, this study suggests that it is important to ensure that the parents understand the
restrictions and management process of phenylketonuria in order to insure their
children’s best future.
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Survey Questions
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Demographics
1. What age group do you fall into?
a. 18-29
b. 30-39
c. 40-49
d. 50-59
2. What is your current marital status?
a. Single
b. Married
c. Divorced
d. Widowed
e. Co-Inhabitants
3. What is your highest level of education completed?
a. Middle school
b. Partial High School
c. Completed High School
d. Partial College
e. Completed College
4. What is your current employment status?
a. Part Time
b. Full Time
c. Unemployed
5. How many children are in your household?
a. 1
b. 2
c. 3
d. 4
e. 5+
6. How many children in your house hold have PKU?
a. 1
b. 2
c. 3
d. 4
e. 5
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7. How old is your child with PKU?
a. 0-3 years old
b. 4-6 years old
c. 7-10 years old
d. 11-12 years old
e. 13-15 years old
8. What is your household income?
a. Under $5,000
b. $5,000 to $9,999
c. $10,000 to $14,999
d. $15,000 to 24,999
e. $25,000 to $34,999
f. $35,000 to $49,999
g. $50,000 to $74,999
h. $75,000 to $99,999
i. $100,000 and over
Understanding of Phenylketonuria
9. What is the cause of PKU?
a. Genetic- passed down through the parents
b. Birth defect
c. Sudden onset illness
d. Poor diet
e. Do not know
10. What is phenylalanine or phe?
a. An amino acid
b. A sugar
c. A fat
d. An antioxidant
11. What is missing in the body that causes PKU?
a. Protein
b. Phenylalanine
c. Enzyme (Phenylalanine Hydroxylase)
d. Carbohydrate
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12. What will happen if a child diagnosed with PKU is not treated or does not follow
their prescribed diet?
a. The child will continue to develop normally
b. The child will become fatigued (tired)
c. The child will develop intellectual disabilities (brain damage or mental retardation)
d. The child will begin to have nausea and vomiting
13. Why is it important for your child to always finish the prescribed amount of formula?
a. To raise the blood phe levels
b. To give the child an appropriate amount of protein
c. To give the child an appropriate fat intake
d. To give the child an appropriate sugar intake
14. What is the main goal of the PKU diet?
a. To reduce the amount of protein eaten
b. To get an appropriate amount of protein with restricted phe
c. To consume a lot of phe
d. To reduce the amount of protein and sugar eaten.
e. Do not know
15. What is the treatment range of phe in the blood in children with PKU?
a. 1.0-2.0 mg/dL
b. 10.0-20.0 mg/dL
c. 2.0-6.0 mg/dL
d. 6.0-10.0 mg/dL
Child Specific Questions
16. My child’s diet is managed by:
a. Counting Phe
b. Counting Protein
c. Using Phe exchanges
d. Estimating phe intake
17. My child participates in his/her care by:
a. Mixing their formula after the appropriate amounts are set out
b. Consuming all their formula
c. Assisting is keeping food records
d. My child does not help in their care management
e. My child is too young to participate in their care management
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18. I am comfortable calculating Phe from foods each day.
□ YES □NO
19. I am comfortable making my child’s formula daily.
□ YES □NO
20. I know which foods my child is not allowed to eat.
□ YES □NO
21. I know which foods my child is allowed to eat and the amounts.
□ YES □NO
22. After receiving my child’s lab values back, if the Phe is high, I plan my child’s diet
with extra care.
□ YES □NO
23. I know the amount of phe my child is allowed to eat each day
□ YES □NO
24. I understand the diet prescription my child is given and how to follow it.
□ YES □NO
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Appendix B
Institutional Review Board Approval
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